Unichem Laboratories has entered into an agreement to acquire 20 per cent stake in the Active Pharmaceutical Ingredient (API) and intermediate business of Hyderabad-based Optimus group. The financial terms of the deal were not disclosed.
The transaction will give Unichem access to Optimus’ US Food and Drug Administration approved API manufacturing facilities, while Optimus will benefit from the knowledge base and industry best practices of Unichem, Unichem Laboratories said in a statement.
Trans-Continental Capital Advisors and Genesis Management Consultancy Services were the financial advisers to the transaction.